Canan Handan, Sizmaz Selçuk, Altan-Yaycioğlu Rana
Department of Ophthalmology, Adana Teaching and Medical Research Center, Baskent University School of Medicine.
Clin Ophthalmol. 2013;7:1597-601. doi: 10.2147/OPTH.S47780. Epub 2013 Aug 8.
The purpose of this study was to evaluate the effectiveness, safety, and incidence of complications after combined clear corneal phacoemulsification with intraocular lens implantation and pars plana vitrectomy in eyes with proliferative diabetic retinopathy coexistent with significant cataract.
Eighty-five eyes of 85 patients with proliferative diabetic retinopathy underwent primary standard three-port vitrectomy with 20-gauge instruments and phacoemulsification with intraocular lens implantation for vitreous hemorrhage from 2008 to 2011. The main outcome measures were visual outcomes and surgical complications.
Forty patients were male and 45 were female. Their age ranged from 40 to 77 years with a mean of 59.6 years. The mean follow-up was 13 months, with a range of 6-48 months. The preoperative logMAR visual acuity changed from 2.62 ± 0.6 to 0.8 ± 0.7 postoperatively. Postoperatively, visual acuity improved in 79 eyes (92.9%), and did not change in six eyes (7.1%). Intraoperative complications were transient corneal edema (five eyes) and posterior capsular rupture (one eye). Postoperative complications consisted of transient intraocular pressure elevation (25 eyes), corneal epithelial defects (six eyes), anterior chamber reaction (four eyes), hyphema (two eyes), posterior synechiae (four eyes), vitreous hemorrhage (23 eyes), retinal tears (five eyes), retinal detachment (one eye), and neovascular glaucoma (one eye).
Our study suggests that the combined operation of pars plana vitrectomy, phacoemulsification, and intraocular lens implantation is safe and effective for patients with proliferative diabetic retinopathy. We believe that the visual outcome and complications depended primarily on underlying posterior segment pathology and were not related to the combined procedure technique.
本研究的目的是评估在伴有严重白内障的增殖性糖尿病视网膜病变患者中,透明角膜超声乳化白内障吸除联合人工晶状体植入术与玻璃体切除术联合应用后的有效性、安全性及并发症发生率。
2008年至2011年,85例增殖性糖尿病视网膜病变患者的85只眼接受了原发性标准三通道20G玻璃体切除术及超声乳化白内障吸除联合人工晶状体植入术,以治疗玻璃体出血。主要观察指标为视力结果和手术并发症。
男性40例,女性45例。年龄范围为40至77岁,平均59.6岁。平均随访时间为13个月,范围为6至48个月。术前logMAR视力从2.62±0.6改善至术后的0.8±0.7。术后,79只眼(92.9%)视力提高,6只眼(7.1%)视力未改变。术中并发症为短暂性角膜水肿(5只眼)和后囊膜破裂(1只眼)。术后并发症包括短暂性眼压升高(25只眼)、角膜上皮缺损(6只眼)、前房反应(4只眼)、前房积血(2只眼)、虹膜后粘连(4只眼)、玻璃体出血(23只眼)、视网膜裂孔(5只眼)、视网膜脱离(1只眼)和新生血管性青光眼(1只眼)。
我们的研究表明,对于增殖性糖尿病视网膜病变患者,玻璃体切除术、超声乳化白内障吸除术和人工晶状体植入术联合应用是安全有效的。我们认为视力结果和并发症主要取决于潜在的后段病变,与联合手术技术无关。